临床肿瘤学杂志 ›› 2018, Vol. 23 ›› Issue (1): 73-78.

• • 上一篇    下一篇

BRAF抑制剂治疗晚期黑色素瘤的研究进展#br#

  

  1. 1 510515 广州中山大学肿瘤医院生物治疗中心 2 200030 上海罗氏制药有限公司医学部

  • 收稿日期:2017-08-10 修回日期:2017-11-07 出版日期:2018-01-30 发布日期:2018-06-28

Progression of BRAF inhibitor on advanced melanoma

  1. Department of Biotherapy, Sun Yatsen University Cancer Center
  • Received:2017-08-10 Revised:2017-11-07 Online:2018-01-30 Published:2018-06-28

摘要: 黑色素瘤是一种恶性的黑色素细胞肿瘤,我国黑色素瘤的发病率逐年攀升,而晚期黑色素瘤在过去几十年里一直没有有效的治疗方法,放疗、化疗及传统免疫治疗效果均不理想,患者预后极差。近年来,随着靶向药物(BRAF抑制剂)在晚期黑色素瘤的治疗上取得突破性进展,为晚期黑色素瘤内科治疗开启了新的篇章。本文通过对国内外具有代表性的临床试验结果的分析,就目前BRAF抑制剂用于治疗晚期黑色素瘤的研究进展作一综述,并初步探讨BRAF抑制剂在晚期黑色素瘤患者中的全程管理问题。

关键词: 晚期黑色素瘤, BRAF V600突变, BRAF抑制剂

Abstract: Melanoma is the most aggressive form of skin tumor caused by excessive proliferation of the abnormal melanocytes with an increasing incidence in recent years in China. However, patients with advanced melanoma had very poor prognosis by traditional therapies. The discovery of prevalent BRAF V600 mutation driving proliferation offers an opportunity to test this oncogenetarget therapy for melanoma. Since 2011, the development of BRAF inhibitor significantly improved the outcome of advanced melanoma treatment, which have brought a hope to the advanced melanoma therapy. This article reviews the mechanism and the current clinical application of BRAF inhibitor from clinical trials in advanced melanoma. In addition, this review will also focus on safety of BRAF inhibitor and treatment selection to obtain maximal benefit in clinical practices.

Key words: Advanced melanoma, BRAF V600 mutation, BRAF inhibitor

No related articles found!
Viewed
Full text


Abstract

Cited

  Shared   
  Discussed   
No Suggested Reading articles found!